AXIOS (Adriel Bettelheim) - AI brings savings to clinical trials: study
Artificial intelligence isn't just speeding up early-stage drug development, it's starting to unlock millions of dollars' worth of new efficiencies in clinical trials on cancer treatments, research shared first with Axios shows. Why it matters: AI-powered tools could shave months off time-consuming processes like recruiting and enrolling patients, monitoring results and interpreting data. - That could free up resources for more clinical studies and possibly lower the high failure rate for new drugs. What they found: A new Tufts Center for the Study of Drug Development analysis found AI agents can accelerate clinical development of cancer drugs by approximately 10 weeks and reduce direct operating costs by as much as $5.6 million in…
What are the identified limitations or challenges regarding the use of AI in clinical trials?
AI does not guarantee trial success, as challenges such as finding the right patients, obtaining consent, and drug manufacturing/distribution remain. Additionally, the need for humans to verify the work of AI agents could offset some of the time savings.
Q&A ID 958b07ad-3e8d-427d-9277-7282fa3e65f5
What are some potential additional uses for AI agents in clinical trials according to Medable officials?
AI agents could be used to track the diversity of the trial population to ensure treatments work for a broad population, and they can enable researchers to understand the safety and effectiveness of a drug earlier, allowing researchers to focus on more strategic work.
Q&A ID ead0ec93-1535-481a-bf19-78d4889800e8
What timeline do Medable officials provide for AI agents becoming standard features in some clinical trials?
Medable officials suggest that AI agents could become standard features of some clinical trials in three to five years, functioning similarly to self-driving cars to handle record-keeping for new drug approval applications.
Q&A ID 01f72621-e4b0-4f74-b424-605111b905e0
What specific efficiencies were observed when Tufts applied a Medable clinical monitoring agent to a phase 2 and 3 oncology drug development program?
Ken Getz, the executive director of the Tufts center, stated that deploying the agent led to efficiencies such as accelerating enrollment in the trial, reducing the number of on-site visits, and locking in the data.
Q&A ID f19c4457-74f0-44f7-8dc8-fcee459514fb
How does the potential net benefit of an experimental cancer treatment change based on the number of tumors it can target, according to research from Tufts?
Efficiencies increase with the number of tumors a drug can target; for example, an experimental treatment with 50 active uses could see net benefits of as much as $565 million.
Q&A ID f1e36742-7ff3-4ae7-9322-ccb357fae820
According to a Tufts Center for the Study of Drug Development analysis, what are the estimated time and cost benefits of using AI agents in late-stage cancer drug clinical trials?
AI agents can accelerate the clinical development of cancer drugs by approximately 10 weeks and reduce direct operating costs by as much as $5.6 million in late-stage trials.
Q&A ID 67e9a6eb-d3ee-4bb2-8940-8eae4453f298